CPHL1P: A Potential Drug Target and Biomarker for ALS-Like conditions

Target Name: CPHL1P

NCBI ID: G389160

CPHL1P

Other Name(s): CPHL1 | ceruloplasmin and hephaestin like 1, pseudogene | Ceruloplasmin and hephaestin-like 1 pseudogene

CPHL1P: A Potential Drug Target and Biomarker for ALS-Like conditions

Introduction

Amyloidosis, a type of cancer-like condition that affects the brain, has been the runner-up cause of human death worldwide, second only to heart disease. The disease is characterized by the accumulation of beta-amyloid peptides in the brain, which cause neurodegeneration and lead to various cognitive and motor impairments. Currently, although there are no specific treatments, research continues to explore new treatments and biomarkers to diagnose and treat this disease. CPHL1P, a genetically encoded protein, has shown potential for drug target specificity in multiple studies and is also considered a potential biomarker. This article will introduce CPHL1P in detail and explore its potential role in the treatment of ALS-like diseases.

Discovery and role of CPHL1P

CPHL1P (c-terminal peptide acyltransferase L1) is a glycoprotein expressed in a variety of tissues and organs. It is responsible for the recognition and clearance of specific glycoproteins and other proteins within cells and plays a key role in the survival and apoptosis of neurons. Research shows that CPHL1P plays an important role in a variety of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and ALS.

First, the role of CPHL1P in Parkinson's disease has been extensively studied. A large number of 伪-presynaptic neuron deaths accumulate in the brains of patients with Parkinson's disease. These neuron deaths may be due to the death of 伪-presynaptic neurons themselves, or may be due to the death of neurons due to external stimulation. CPHL1P plays a key role in neuronal survival and apoptosis. Studies have shown that CPHL1P expression is upregulated in the brains of Parkinson's disease patients, which may reflect CPHL1P as a potential target for the treatment of Parkinson's disease.

Secondly, CPHL1P also plays an important role in Alzheimer's disease. People with Alzheimer's disease develop neuroamyloid plaques in the brain, which are caused by neuron death and synaptic damage. CPHL1P plays a key role in neuronal survival and apoptosis, and studies have shown that CPHL1P expression is upregulated in the brains of Alzheimer's disease patients, which may reflect CPHL1P as a potential target for the treatment of Alzheimer's disease.

Finally, CPHL1P also plays an important role in ALS. ALS is a neurodegenerative disease characterized by neuronal death and neuronal damage. CPHL1P plays a key role in neuronal survival and apoptosis, and studies have shown that CPHL1P expression is upregulated in the brains of ALS patients, which may reflect CPHL1P as a potential target for the treatment of ALS.

Biological functions and pharmacological significance of CPHL1P

As a protein, CPHL1P has multiple biological functions. First, CPHL1P is a glycoprotein responsible for recognizing and clearing specific glycoproteins and other proteins. This function makes CPHL1P an ideal drug target that can specifically inhibit the function of CPHL1P to treat various diseases.

Secondly, CPHL1P is responsible for clearing specific proteins within cells, such as 尾-amyloid peptide, which is a major factor in neuronal death. Research suggests that CPHL1P can clear beta-amyloid peptides, potentially serving as a treatment for neurodegenerative diseases.

Finally, CPHL1P plays a critical role in neuronal survival and apoptosis. Neuron death and apoptosis are the main features of neurodegenerative diseases, and CPHL1P plays a key role in neuronal survival and apoptosis, which provides new ideas for the treatment of these diseases.

Pharmacological significance of CPHL1P

CPHL1P, as a protein, has multiple pharmacological implications. First, CPHL1P can serve as a potential target for the treatment of neurodegenerative diseases. Although there are currently no specific drugs to treat neurodegenerative diseases, research continues to explore new treatments and biomarkers to diagnose and treat these diseases. As a protein, CPHL1P has multiple biological functions and provides new ideas for the treatment of neurodegenerative diseases.

Secondly, CPHL1P can serve as a biomarker to assess disease severity. Currently, although there are no

Protein Name: Ceruloplasmin And Hephaestin Like 1, Pseudogene

The "CPHL1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPHL1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets